Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B) | SciPort RLP

Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)

Laufzeit: 01.01.2023 - 31.12.2030

imported

Kurzfassung

-

Beteiligte Einrichtungen